Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
March 2017
-
Media ReleaseNovartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority ReviewPriority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the…
-
Media ReleaseAlcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correctionThe unique optical design of the ACTIVEFOCUS(TM) toric IOL gives astigmatic cataract patients quality distance vision and an increased range of vision to potentially reduce dependence on glasses…
-
Media ReleaseNovartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failurePhase III RELAX-AHF-2 study did not meet primary endpoints of reduced cardiovascular death or worsening heart failure in patients with acute heart failure Novartis remains committed to…
-
Media ReleaseNovartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasisNew data suggests that disease modification with Cosentyx may be achievable for around 20% of patients following one year of treatment[1] Patients with longer disease duration before…
-
Media ReleaseNew analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetesNew post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced…
-
Media ReleaseNovartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitorApproved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
-
Media ReleaseSandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)Three winners, chosen by expert panel at Wired Health 2017 in London, identified innovative approaches to address access challenges in Ghana, the Maldives and the Philippines. Winning ideas…
-
Media ReleaseNovartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pauseNew analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and…
-
Media ReleaseNew data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicineSandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017…
February 2017
-
Media ReleaseNovartis shareholders approve all resolutions proposed by Board of Directors at the Annual General MeetingShareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt…
-
Media ReleaseNovartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patientsIf approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients…
-
Media ReleaseNovartis drug Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLCPriority Review based on Phase III study results showing 16.6 month median progression-free survival in previously untreated ALK+ metastatic NSCLC patients on Zykadia vs. 8.1 months treated with…
Pagination
- ‹ Previous page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- …
- 88
- › Next page